Streetbeat News

Regulatory

DARE

Daré Bioscience announced the publication of data from a Phase 1/2 clinical trial of DARE-HRT1, a potential first FDA-approved monthly intravaginal ring for hormone therapy. The company plans to advance DARE-HRT1 into a single Phase 3 clinical trial for the treatment of vasomotor symptoms due to menopause.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:19 pm

OCUP

Ocuphire Pharma announced that Dr. Victor H. Gonzalez will present late breaking clinical data on APX3330 ZETA-1 at the American Diabetes Association Annual Conference. The presentation will focus on the efficacy and safety results of the ZETA-1 Phase 2 trial in diabetic retinopathy.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:18 pm

DMAC

DiaMedica Therapeutics (NASDAQ:DMAC) announced that the FDA has removed the clinical hold on its ReMEDy2 phase 2/3 trial for DM199 in the treatment of acute ischemic stroke (AIS). The trial is set to resume as soon as possible, with the potential to serve as a pivotal registration study of DM199 in this patient population.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:16 pm

ASMB

Assembly Biosciences presented new data on its hepatitis D and B virus antiviral pipeline at the International Liver Congress, showcasing promising results for its entry inhibitor and core inhibitor programs. The company expects to nominate a development candidate for its entry inhibitor program this year.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:16 pm

SCHW

The EDX Exchange, a new non-custodial platform for trading cryptocurrencies, has gained backing from Charles Schwab (NYSE:SCHW), Fidelity Digital Assets, and Citadel Securities. Despite this support, Charles Schwab's daughter, Carrie Schwab-Pomerantz, has labeled cryptocurrency as 'gambling'.

Portfolio Pulse from Mehab Qureshi

June 21, 2023 | 12:15 pm

PETV

PetVivo Holdings has received an initial regulatory assessment for its proprietary Biomatrix Particulate Technology, which could lead to approval for various human products. The company plans to complete regulatory plans for new human products by the first part of 2024.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:13 pm

CATX

Perspective Therapeutics has initiated clinical trial sites and started enrolling patients for its 212Pb-labeled therapeutic product candidates, VMT-α-NET and VMT01 for melanoma. Preliminary results from initial cohorts are expected by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 12:07 pm

GSK

GSK announced positive results from the AReSVi-006 Phase 3 trial of Arexvy, a respiratory syncytial virus (RSV) vaccine for adults aged 60 years and older. The vaccine demonstrated efficacy over two full RSV seasons, including in participants with underlying medical conditions.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 12:04 pm

USO

Russia's crude oil exports to China reached a record high in May, with a 15.3% YoY increase and a 32.4% MoM jump. This comes as Europe applies sanctions on Russian crude oil due to the Russia-Ukraine war, causing Russia's fuel exports to EU member states to fall 90% YoY.

Portfolio Pulse from Shanthi Rexaline

June 21, 2023 | 12:04 pm

BIVI

BioVie is set to present data from its NE3017 study in Alzheimer's disease at the 83rd Scientific Sessions of the American Diabetes Association on June 24.

Portfolio Pulse from Bill Haddad

June 21, 2023 | 12:03 pm